UNSPSC 51393311: Neraminol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H26N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H5HKR8OEF3, chemically known as (- )-1-(1h-indazol-4-yloxy)-3-((2-(2,6-xylidino)ethyl)amino)-2-propanol but generally known as neraminol, which bears US NIH Compound Identifier 3047789. European Medicines Agency schedules Neraminol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09203MIG.

UNSPSC 51393311 Neraminol is a Commodity code that encompasses pharmaceutical products used in emergency response and harm-reduction initiatives, though recent state and local solicitations show limited activity directly aligned with this specific product code. Seminole County, Florida's IFB60459723LAS procurement sought naloxone and safe drug deactivation systems — products related to overdose prevention and emergency medicine rather than neraminol specifically — through an annual competitive bidding process with quarterly deliveries to a county health facility. The Texas Health and Human Services Commission's RFI HHS0017013 addressed direct-to-manufacturer prescription fulfillment strategies without specifying neraminol or related pharmaceutical commodities. State and local issuing bodies pursuing this code appear to include county health departments and state health agencies focused on community health and pharmacy benefit management, though the recent opportunities show broader procurement scope than the code's nominal product category.

Geographic activity under this code is limited to two states in the recent record: Florida, where Seminole County posted a competitive IFB with a July 26, 2023 response deadline (though the posting date of June 30, 2026 suggests a data inconsistency), and Texas, where the state health commission issued an April 3, 2026 RFI to explore direct pharmaceutical procurement mechanisms. The Seminole County solicitation required vendors to supply 1,900 units of naloxone and 800 safe drug deactivation systems annually with electronic bid submission, E-Verify compliance, and standard insurance and drug-free workplace certifications. The Texas RFI functioned as preliminary market research to inform future formal procurement rather than a direct purchase solicitation. Overall activity under this specific commodity code appears sparse; recent opportunities show health agencies buying pharmaceutical products and services that do not neatly align with neraminol specifically, suggesting the code may see limited state and local application or that buyers are tagging related procurement under broader pharmaceutical or health-supply categories.